[go: up one dir, main page]

ES8307501A1 - "un procedimiento para preparar una forma de dosificacion unitaria adecuada para el tratamiento de una enfermedad asociada con un alelo de un gen de la respuesta inmune". - Google Patents

"un procedimiento para preparar una forma de dosificacion unitaria adecuada para el tratamiento de una enfermedad asociada con un alelo de un gen de la respuesta inmune".

Info

Publication number
ES8307501A1
ES8307501A1 ES513444A ES513444A ES8307501A1 ES 8307501 A1 ES8307501 A1 ES 8307501A1 ES 513444 A ES513444 A ES 513444A ES 513444 A ES513444 A ES 513444A ES 8307501 A1 ES8307501 A1 ES 8307501A1
Authority
ES
Spain
Prior art keywords
immune response
gene
wing
preparing
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES513444A
Other languages
English (en)
Other versions
ES513444A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of ES8307501A1 publication Critical patent/ES8307501A1/es
Publication of ES513444A0 publication Critical patent/ES513444A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE COMPOSICIONES, QUE TIENEN APLICACIONES PARA EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON GENES DE RESPUESTA INMUNE LIGADA A CHP (COMPLEJO DE HISTOCOMPATIBILIDAD PRINCIPAL). CONSISTE EN RECOGER LINFOCITOS DE INDIVIDUOS QUE TIENEN ELEVADOS TITULOS DE ANTICUERPO CONTRA EL PRODUCTO DE GEN DE RESPUESTA INMUNE LIGADA A CHP; FUSIONAR LOS LINFOCITOS CON CELULAS TUMORALES; RECOGER EL ANTICUERPO MONOCLONAL DE LOS HIBRIDOMAS ASI FORMADOS; Y FORMULAR EL ANTICUERPO CON UN VEHICULO PARENTERAL FISIOLOGICAMENTE COMPATIBLE.
ES513444A 1981-06-25 1982-06-25 "un procedimiento para preparar una forma de dosificacion unitaria adecuada para el tratamiento de una enfermedad asociada con un alelo de un gen de la respuesta inmune". Granted ES513444A0 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27739881A 1981-06-25 1981-06-25
US30459581A 1981-09-22 1981-09-22

Publications (2)

Publication Number Publication Date
ES8307501A1 true ES8307501A1 (es) 1983-08-01
ES513444A0 ES513444A0 (es) 1983-08-01

Family

ID=26958458

Family Applications (1)

Application Number Title Priority Date Filing Date
ES513444A Granted ES513444A0 (es) 1981-06-25 1982-06-25 "un procedimiento para preparar una forma de dosificacion unitaria adecuada para el tratamiento de una enfermedad asociada con un alelo de un gen de la respuesta inmune".

Country Status (4)

Country Link
EP (1) EP0068790B1 (es)
JP (1) JP2555301B2 (es)
DE (1) DE3269354D1 (es)
ES (1) ES513444A0 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59231024A (ja) * 1983-06-14 1984-12-25 Medekusu:Kk 自己免疫疾患に対する治療薬
JPS6011430A (ja) * 1983-06-30 1985-01-21 Medekusu:Kk 腎疾患に対する治療薬
JPS6041616A (ja) * 1983-08-12 1985-03-05 Medekusu:Kk 腎疾患に対する治療薬
DE3687064T2 (de) * 1985-06-14 1993-11-11 Bristol Myers Squibb Co Verfahren zur identifizierung von mit gesteigerter diabetesgefahr assoziierten allelen.
US6045796A (en) * 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
PL320610A1 (en) * 1994-12-07 1997-10-13 Hoffmann La Roche Fragments of monoclonal antibodies of immunosuppressive activity
WO1996020215A2 (en) * 1994-12-23 1996-07-04 Laboratoires Om S.A. Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
DE19531346A1 (de) 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen

Also Published As

Publication number Publication date
JP2555301B2 (ja) 1996-11-20
EP0068790A3 (en) 1983-06-29
DE3269354D1 (en) 1986-04-03
EP0068790A2 (en) 1983-01-05
EP0068790B1 (en) 1986-02-26
ES513444A0 (es) 1983-08-01
JPS5899422A (ja) 1983-06-13

Similar Documents

Publication Publication Date Title
Staveley-O’Carroll et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression
ES2104565T3 (es) Determinantes anti-receptor de celulas t como tratamiento de enfermedades autoinmunes.
AU621830B2 (en) Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
NL300351I1 (nl) Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor
Tan et al. The role of chemokines in cutaneous immunosurveillance
ES8307501A1 (es) "un procedimiento para preparar una forma de dosificacion unitaria adecuada para el tratamiento de una enfermedad asociada con un alelo de un gen de la respuesta inmune".
GB1499035A (en) Antistaphylococcus human immune globulin and method of preparing same
DE59608213D1 (de) Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
EP0674661A4 (en) TITRATION AND TREATMENT FOR DEMYELINIZING DISEASES SUCH AS MULTIPLE SCLEROSIS.
Mckinney et al. Effects of reserpine on the social behavior of rhesus monkeys.
Shirakawa et al. Immunosuppressive factors from adult T-cell leukemia cells
FI875245A0 (fi) Foerfarande foer oekande av utsoendringen av adenosin.
EP0194851A3 (en) Human tumor therapy
SE8404283L (sv) Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
EP0572508A4 (en) NUCLEIC ACID ENCODING THE INSULIN RECEPTOR SUBSTRATE-1 (IRS-1), IRS-1 PROTEIN, DISEASES AND THERAPY ASSOCIATED WITH IRS-1 METABOLISM.
NO930798L (no) Fremgangsmaate og middel mot tumorer
IT1195940B (it) Procedimento per la produzione di interferone da geni umani
Taira et al. The regulatory role of sialic acids in the response of class II reactive T cell hybridomas to allogeneic B cells.
FI854839A0 (fi) Vaccin eller diagnostisk produkt erhaollen fraon peptid, samt daeri anvaendbar polypeptid.
Li et al. ALLOREACTIVE ANTI-HLA-B7 CYTOLYTIC T CELL CLONES USE RESTRICTED T CELL RECEPTOR GENES1
Cupedo et al. Development and structure of lymph nodes in humans and mice
DE69232140D1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
Zimmer Alessandro Moretta and Transporter Associated With Antigen Processing (TAP) Deficiency: On Giant's Shoulders

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20020506